A retrospective study analysing safety and efficacy of checkpoint inhibitors in metastatic non-clear cell renal cell carcinoma and clear cell renal cell carcinoma with variant features
Latest Information Update: 20 Jun 2020
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma; Rhabdoid tumour; Sarcoma
- Focus Therapeutic Use
Most Recent Events
- 20 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology